BG Medicine, Inc. (BGMD)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2015 | -5.05 Million USD | 38.27% |
| 2014 | -7.2 Million USD | 48.74% |
| 2013 | -14.75 Million USD | 5.06% |
| 2012 | -22.41 Million USD | 13.31% |
| 2011 | -17.07 Million USD | -22.03% |
| 2010 | -13.83 Million USD | 6.0% |
| 2009 | -15.23 Million USD | -52.36% |
| 2008 | -9.98 Million USD | 0.0% |
| 2006 | -3.53 Million USD | 53.98% |
| 2005 | -6.65 Million USD | 45.72% |
| 2004 | -6.82 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2015 FY | - USD | 38.27% |
| 2015 Q3 | -1 Million USD | 30.17% |
| 2015 Q4 | -884 Thousand USD | 12.39% |
| 2015 Q1 | -1.25 Million USD | -3.72% |
| 2015 Q2 | -1.44 Million USD | -15.05% |
| 2014 Q1 | -1.91 Million USD | -15.25% |
| 2014 FY | - USD | 48.74% |
| 2014 Q3 | -2.2 Million USD | -13.58% |
| 2014 Q4 | -1.21 Million USD | 44.95% |
| 2014 Q2 | -1.93 Million USD | -1.31% |
| 2013 Q3 | -3.22 Million USD | 29.03% |
| 2013 FY | - USD | 5.06% |
| 2013 Q2 | -4.54 Million USD | 5.29% |
| 2013 Q1 | -4.79 Million USD | -78.99% |
| 2013 Q4 | -1.65 Million USD | 48.54% |
| 2012 Q3 | -6.48 Million USD | -7.58% |
| 2012 Q2 | -6.02 Million USD | 18.67% |
| 2012 Q1 | -7.41 Million USD | -59.8% |
| 2012 FY | - USD | 13.31% |
| 2012 Q4 | -2.68 Million USD | 58.68% |
| 2011 Q4 | -4.63 Million USD | 4.11% |
| 2011 Q1 | -2.82 Million USD | 2.18% |
| 2011 Q2 | -4.72 Million USD | -67.03% |
| 2011 FY | - USD | -22.03% |
| 2011 Q3 | -4.83 Million USD | -2.46% |
| 2010 Q4 | -2.89 Million USD | 15.89% |
| 2010 FY | - USD | 6.0% |
| 2010 Q3 | -3.43 Million USD | -0.41% |
| 2010 Q2 | -3.42 Million USD | 24.77% |
| 2010 Q1 | -4.54 Million USD | -16.02% |
| 2009 Q4 | -3.92 Million USD | 6.35% |
| 2009 FY | - USD | -52.36% |
| 2009 Q3 | -4.18 Million USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q3 | -1.99 Million USD | -5.27% |
| 2007 Q2 | -1.89 Million USD | -36.9% |
| 2007 Q1 | -1.38 Million USD | -949.69% |
| 2006 FY | - USD | 53.98% |
| 2006 Q3 | -997 Thousand USD | -8.84% |
| 2006 Q1 | -1.78 Million USD | 0.0% |
| 2006 Q2 | -916 Thousand USD | 48.74% |
| 2006 Q4 | 163 Thousand USD | 116.35% |
| 2005 FY | - USD | 45.72% |
| 2004 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Medical Technologies Inc. | -963.95 Thousand USD | 100.0% |
| Ansell Limited | 209.86 Million USD | 100.0% |
| Ansell Limited | 206.3 Million USD | 100.0% |
| Biotage AB (publ) | 42.83 Million USD | 100.0% |
| BioLife Sciences Inc. | - USD | NaN% |
| CB Scientific, Inc. | -1.62 Million USD | 100.0% |
| Psykey, Inc. | -1.29 Million USD | 100.0% |
| ConvaTec Group Plc | 455.5 Million USD | 100.0% |
| ConvaTec Group Plc | 455.5 Million USD | 100.0% |
| Encision Inc. | -544.19 Thousand USD | 100.0% |
| Golden Valley Development, Inc | -141.81 Thousand USD | 100.0% |
| Hear AtLast Holdings, Inc. | -109.93 Thousand USD | 100.0% |
| Innovative MedTech Inc. | -7.67 Million USD | 100.0% |
| LifePoint, Inc. | -14.2 Million USD | 100.0% |
| Medite Cancer Diagnostics, Inc. | -6.18 Million USD | 100.0% |
| Paradigm Medical Industries, Inc. | -325 Thousand USD | 100.0% |
| QuantRx Biomedical Corporation | - USD | NaN% |
| Remedent, Inc. | -215.23 Thousand USD | 100.0% |
| Reflect Scientific, Inc. | -405.78 Thousand USD | 100.0% |
| SmileDirectClub, Inc. | -186.13 Million USD | 100.0% |
| Sector 10, Inc. | - USD | NaN% |
| Shandong Weigao Group Medical Polymer Company Limited | 447.82 Million USD | 100.0% |
| SheerVision, Inc. | -110.53 Thousand USD | 100.0% |
| United Health Products, Inc. | -2.5 Million USD | 100.0% |
| Vasamed, Inc. | -4.57 Million USD | 100.0% |
| Wearable Health Solutions, Inc. | -2.26 Million USD | 100.0% |
| Yubo International Biotech Limited | -1.17 Million USD | 100.0% |